2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic

Program: Oral Abstract Session
Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - R06-R09
Technology and Procedures, Imaging, Omics Technologies, Computational Biology, Gene Editing, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Study Population, Human, Animal Model
PAPER

212 The importin KPNA4 drives chemoresistance in acute myeloid leukemia by sustaining DNA repair under replication stress

Amit Kumar, PhD, Veronique Voisin, PhD2, Dakai Ling3, Rose Hurren4, Jonathan St-Germain5, Mark Minden Sr, MD PhD6, Brian Raught7, Aaron Schimmer, MD PhD8, Grace Egan, MD, PhD9
1 The Hospital for Sick Children, Toronto, Canada
2 The Hospital for Sick Children, Toronto, Canada
3 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
4 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
5 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
6 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
7 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
8 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
9 The Hospital for Sick Children, Toronto, Canada

Acute myeloid leukemia (AML) is an aggressive disease in which chemoresistance and relapse drive mortality. Despite the success of recent targeted therapies, responses are rarely durable. With intensive chemotherapy at the ceiling of tolerable toxicity, new strategies to enhance chemotherapy response are needed. Transport of proteins into the nucleus is a central oncogenic dependency in AML, regulating the localization of transcription factors, DNA repair enzymes, and ribosomal proteins that sustain leukemic survival. To date, targeting this process has centered on pan-essential receptors such as XPO1, but clinical efficacy is limited by on-target toxicity in normal tissues. Whether AML harbors non-essential nuclear transport receptors that can be selectively targeted to enhance chemotherapy response remains an unanswered question.

We hypothesized that individual members of the importin α family (KPNA1–7), which selectively import distinct protein cargo into the nucleus, could function as leukemia-selective dependencies. We identified KPNA4 as a non-essential nuclear transport receptor selectively required for AML survival.

KPNA4 showed the highest mRNA expression among KPNA family members in AML relative to normal hematopoietic stem/progenitor cells (HSPCs; P = 4.3 × 10?6). Immunoblotting confirmed elevated KPNA4 protein expression in primary patient AML cells but not normal HSPCs (P < 0.01). KPNA4 mRNA expression was highest in relapsed AML (P = 0.005) and showed the strongest association with a leukemia stem cell (LSC+) signature among KPNA family members (GSE13159). KPNA4 was expressed across cytogenetic subgroups, consistent with a dependency not confined to a genetically defined subset. KPNA4 was the only KPNA family member associated with inferior overall survival in Beat AML by Cox proportional hazards analysis (P = 0.048), with a similar association in TCGA (P = 0.013). In TARGET, high KPNA4 expression was associated with inferior event-free (P = 0.034) and overall survival (P = 0.015) by Kaplan-Meier analysis.

KPNA4 depletion by shRNA and CRISPR-Cas9 reduced proliferation, viability, and clonogenicity across AML cell lines (OCI-AML2, TEX, NB4, MOLM13, and MV4-11), with the greatest effect on clonogenicity, implicating a functional impact on leukemic stem cells. Importantly, KPNA4 depletion reduced engraftment of TEX cells (P < 0.001) and primary patient AML cells (P = 0.008) into mouse marrow, but did not impair engraftment of normal cord blood (P = 0.59), demonstrating a therapeutic window.

To understand the function and cargos of KPNA4, we mapped the KPNA4 interactome by proximity-dependent biotinylation (BioID) and mass spectrometry. KPNA4 interactors were enriched for proteins involved in the DNA damage response (DDR). Comparison with published importin α interactomes (PXD007976) revealed KPNA4 bound DDR proteins not shared with KPNA1, KPNA2, or KPNA5. Specifically, KPNA4 interacted with MCM8 and MCM9, which form a helicase complex that stabilizes stalled replication forks and mediates their repair by homologous recombination. Proximity ligation assay confirmed both interactions. KPNA4 depletion reduced MCM8 and MCM9 nuclear localization by immunoblotting and increased baseline γH2AX.

Given that KPNA4 expression was highest in relapsed disease and that KPNA4 imports DDR proteins, we examined the impact of KPNA4 depletion on chemosensitivity. Compared with control, KPNA4-depleted AML cells were profoundly sensitized to cytarabine (~5-fold reduction in IC50, P < 0.0001), a nucleoside analog and backbone of AML induction chemotherapy that induces replication fork stalling. KPNA4 depletion also increased γH2AX accumulation following cytarabine exposure, consistent with defective recovery from stalled forks. These findings establish a mechanism whereby KPNA4 promotes chemoresistance by importing the MCM8-MCM9 complex to enable fork stabilization and recovery under replication stress and chemotherapy exposure.

Collectively, our data identify KPNA4 as a novel leukemia-selective nuclear transport receptor that sustains DNA repair under replication stress and contributes to chemoresistance in AML. KPNA4 depletion sensitizes AML cells to cytarabine and is tolerated by normal hematopoietic cells. Thus, our work nominates KPNA4 as a selective target to enhance chemotherapy response in AML.

Grace Egan, MD, PhD: No relevant conflicts of interest to declare.